The medicine is Bluey
Ask a kid to wear an eyepatch for two hours a day and you have started a small domestic war. Ask the same kid to watch an hour of their favorite show, and you have a willing patient. Scott Xiao built a company on the gap between those two sentences.
As co-founder and CEO of Luminopia, Xiao runs a Cambridge, Massachusetts company whose lead product, Luminopia One, is a prescription treatment for amblyopia - the leading cause of vision loss in children. A kid puts on a VR headset, picks a show, and watches. Behind the cartoon, software is quietly altering the image fed to each eye, dimming and reshaping it to coax the weaker eye back to work and to teach the brain to fuse both signals. The patient thinks they are watching DreamWorks. The patient is taking a dose.
"We're actually altering the image parameters in real time, with the goal of promoting weaker eye usage and encouraging patients' brains to combine input from both eyes."
For roughly two hundred years, the standard answer to a lazy eye was to cover the strong one and wait. Patches and drops. Cheap, proven, and quietly miserable for the children expected to comply with them. Xiao's bet was that compliance is itself the medicine - that a treatment kids actually finish beats a better one they abandon. The clinical data backed the instinct: in the trial that supported approval, 88% of children stuck with Luminopia, and 94% of parents preferred it to patching.
OriginsA friend, a class project, a dropout
The company started with a story someone told Xiao. A Harvard classmate had grown up with amblyopia and described the grind of the old treatments. Xiao and his co-founder, Dean Travers, were genuinely surprised that patches and drops were still the frontier for a condition this common. The surprise did not fade. It became a computer-science class project - an early prototype that delivered separate images to each eye.
They showed it to the Ophthalmologist-in-Chief at Boston Children's Hospital. The feedback was promising enough that two undergraduates decided Harvard could wait. Luminopia was founded in 2017. Travers, a Thiel Fellow, would later move to the board; Xiao took the CEO seat and the long regulatory road that came with it.
"We live in a time where great technological innovations are popping up left and right - not nearly enough of them are being used to improve patient care."
The science came from Boston Children's Hospital and MIT. The fun came from Hollywood. To make an hour of daily therapy something a four-year-old would request, Luminopia needed content kids loved, so Xiao went and got it: deals with Sesame Workshop, Nickelodeon, DreamWorks, and NBC, adding up to more than a hundred hours of programming. Sesame did not just license shows - through Sesame Ventures, it invested. So did Robert Langer, the MIT scientist who co-founded Moderna, and Jeffrey Dunn, the former Sesame Workshop CEO who joined as a backer.
Lines on a chart
A randomized controlled trial of 105 children, published in 2021, gave Xiao the number that mattered. Children using Luminopia improved their vision by an average of 1.8 lines on a standard eye chart over 12 weeks. The control group improved 0.8 lines. The gap was the whole argument: a screen, properly programmed, can do measurable clinical work.
That data took Luminopia One through the FDA's De Novo pathway, the route reserved for genuinely new kinds of device. In 2021 it cleared - the first virtual-reality therapeutic the agency had ever approved for any medical condition. TIME named it one of the Best Inventions of 2023. By then a $16 million Series A had pushed total funding to around $34 million, and the product was being prescribed at children's hospitals and eye institutes across the country.
"It's not about who comes up with an idea, it's about how we can find the best solution."
Under-promise, ship the rest
Xiao entered healthcare knowing almost nothing about it and learned fast - the kind of founder who treats domain ignorance as a deadline rather than a disqualification. Ask him what carries a company through a six-year regulatory slog and he does not point at the technology. He points at the people in the room.
"The most important element is the people you have beside you. Everything a company does stems from the people who are in it."
His stated ambition runs past Luminopia's first product. He wants to pull more talented people into healthcare technology, and to build out a category - software-based treatments for neuro-visual disorders that, by the company's count, affect roughly 15 million Americans. Real-world data from the Prescription Luminopia Registry, reported in early 2026, keeps showing the approved therapy holding up outside the trial. The awards have piled up to match: Forbes 30 Under 30, MIT Technology Review's Innovators Under 35, and a spot on Modern Healthcare's 40 Under 40 in 2025.
The pitch never gets less strange when you say it plainly. A doctor writes a prescription. The prescription is screen time. The pharmacy is a cartoon library curated by Sesame Street. And the patient, for once, is glad to take their medicine.